Theriva Biologics, Inc. (TOVX)
0.2411
0.00 (0.00%)
USD |
NYAM |
Jun 10, 16:00
0.2288
-0.01
(-5.10%)
After-Hours: 20:00
Theriva Biologics Enterprise Value : 0.3543M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 0.3543M |
| June 08, 2026 | 1.148M |
| June 05, 2026 | 0.9738M |
| June 04, 2026 | 2.227M |
| June 03, 2026 | 2.479M |
| June 02, 2026 | 2.387M |
| June 01, 2026 | 2.204M |
| May 29, 2026 | 2.286M |
| May 28, 2026 | 3.443M |
| May 27, 2026 | 2.768M |
| May 26, 2026 | 2.892M |
| May 22, 2026 | 3.672M |
| May 21, 2026 | 2.874M |
| May 20, 2026 | 3.030M |
| May 19, 2026 | 1.511M |
| May 18, 2026 | 2.805M |
| May 15, 2026 | 2.617M |
| May 14, 2026 | 3.994M |
| May 13, 2026 | 4.407M |
| May 12, 2026 | 4.035M |
| May 11, 2026 | 4.911M |
| May 08, 2026 | 5.508M |
| May 07, 2026 | 5.783M |
| May 06, 2026 | 6.793M |
| May 05, 2026 | 6.706M |
| Date | Value |
|---|---|
| May 04, 2026 | 6.688M |
| May 01, 2026 | 7.142M |
| April 30, 2026 | 5.719M |
| April 29, 2026 | 4.407M |
| April 28, 2026 | 5.664M |
| April 27, 2026 | 5.494M |
| April 24, 2026 | 6.747M |
| April 23, 2026 | 6.747M |
| April 22, 2026 | 6.385M |
| April 21, 2026 | 4.806M |
| April 20, 2026 | 8.078M |
| April 17, 2026 | 1.066M |
| April 16, 2026 | 0.8407M |
| April 15, 2026 | 0.9692M |
| April 14, 2026 | 0.3221M |
| April 13, 2026 | 0.8774M |
| April 10, 2026 | -0.1506M |
| April 09, 2026 | 1.066M |
| April 08, 2026 | 2.892M |
| April 07, 2026 | 0.7122M |
| April 06, 2026 | 0.6663M |
| April 02, 2026 | -0.1873M |
| April 01, 2026 | -0.3387M |
| March 31, 2026 | -1.752M |
| March 30, 2026 | -3.818M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.936B |
| Alnylam Pharmaceuticals, Inc. | 39.69B |
| Savara, Inc. | 837.60M |
| Vericel Corp. | 1.840B |
| Biogen, Inc. | 31.67B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.044M |
| Revenue (Quarterly) | 0.30M |
| Total Expenses (Quarterly) | 2.344M |
| EPS Diluted (Quarterly) | -0.0498 |
| Gross Profit Margin (Quarterly) | 92.00% |
| Profit Margin (Quarterly) | -681.3% |
| Earnings Yield | -1.05K% |
| Normalized Earnings Yield | -662.96 |